Aminosalicylic acid: Difference between revisions

Jump to navigation Jump to search
m (Protected "Aminosalicylic acid": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 25: Line 25:
{{CMG}}
{{CMG}}


{{EH}}
 


'''Aminosalicylic acid''', also known as '''''para''-aminosalicylic acid''', '''''p''-aminosalicylic acid''' or '''4-aminosalicylic acid'''; abbreviated '''4-ASA''', '''PAS''' or '''P''', is an [[antibiotic]] used to treat [[tuberculosis]]. It has been use for over forty years in the treatment of [[inflammatory bowel disease]]s (IBDs), where it has shown greater potency in [[Crohn's disease]]. It is thought to act via [[NF-kB|NF-κB]] (nuclear factor-kappa B) inhibition and free radical scavenging.
'''Aminosalicylic acid''', also known as '''''para''-aminosalicylic acid''', '''''p''-aminosalicylic acid''' or '''4-aminosalicylic acid'''; abbreviated '''4-ASA''', '''PAS''' or '''P''', is an [[antibiotic]] used to treat [[tuberculosis]]. It has been use for over forty years in the treatment of [[inflammatory bowel disease]]s (IBDs), where it has shown greater potency in [[Crohn's disease]]. It is thought to act via [[NF-kB|NF-κB]] (nuclear factor-kappa B) inhibition and free radical scavenging.
Line 63: Line 63:


{{Antimycobacterials}}
{{Antimycobacterials}}
{{SIB}}
 


[[Category:Tuberculosis]]
[[Category:Tuberculosis]]

Revision as of 22:05, 8 August 2012

Aminosalicylic acid
Clinical data
Pregnancy
category
  • C
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Protein binding50–60%
MetabolismHepatic
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC7H7NO3
Molar mass153.135 g/mol
3D model (JSmol)
Melting point150.5 °C (302.9 °F)

WikiDoc Resources for Aminosalicylic acid

Articles

Most recent articles on Aminosalicylic acid

Most cited articles on Aminosalicylic acid

Review articles on Aminosalicylic acid

Articles on Aminosalicylic acid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aminosalicylic acid

Images of Aminosalicylic acid

Photos of Aminosalicylic acid

Podcasts & MP3s on Aminosalicylic acid

Videos on Aminosalicylic acid

Evidence Based Medicine

Cochrane Collaboration on Aminosalicylic acid

Bandolier on Aminosalicylic acid

TRIP on Aminosalicylic acid

Clinical Trials

Ongoing Trials on Aminosalicylic acid at Clinical Trials.gov

Trial results on Aminosalicylic acid

Clinical Trials on Aminosalicylic acid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aminosalicylic acid

NICE Guidance on Aminosalicylic acid

NHS PRODIGY Guidance

FDA on Aminosalicylic acid

CDC on Aminosalicylic acid

Books

Books on Aminosalicylic acid

News

Aminosalicylic acid in the news

Be alerted to news on Aminosalicylic acid

News trends on Aminosalicylic acid

Commentary

Blogs on Aminosalicylic acid

Definitions

Definitions of Aminosalicylic acid

Patient Resources / Community

Patient resources on Aminosalicylic acid

Discussion groups on Aminosalicylic acid

Patient Handouts on Aminosalicylic acid

Directions to Hospitals Treating Aminosalicylic acid

Risk calculators and risk factors for Aminosalicylic acid

Healthcare Provider Resources

Symptoms of Aminosalicylic acid

Causes & Risk Factors for Aminosalicylic acid

Diagnostic studies for Aminosalicylic acid

Treatment of Aminosalicylic acid

Continuing Medical Education (CME)

CME Programs on Aminosalicylic acid

International

Aminosalicylic acid en Espanol

Aminosalicylic acid en Francais

Business

Aminosalicylic acid in the Marketplace

Patents on Aminosalicylic acid

Experimental / Informatics

List of terms related to Aminosalicylic acid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Aminosalicylic acid, also known as para-aminosalicylic acid, p-aminosalicylic acid or 4-aminosalicylic acid; abbreviated 4-ASA, PAS or P, is an antibiotic used to treat tuberculosis. It has been use for over forty years in the treatment of inflammatory bowel diseases (IBDs), where it has shown greater potency in Crohn's disease. It is thought to act via NF-κB (nuclear factor-kappa B) inhibition and free radical scavenging.

Aminosalicylic acid is sold in the United States by Jacobus Pharmaceutical as Paser. Mesalazine (5-aminosalicylic acid) is a closely related compound that also has medical uses.

Medical uses

Aminosalicylic acid was introduced to clinical use in 1948. It was the second antibiotic found to be effective in the treatment of tuberculosis (after streptomycin).

Its potency is less than that of the current five first-line drugs (isoniazid, rifampicin, ethambutol, pyrazinamide and streptomycin) for treating tuberculosis. It still has a role to play in the treatment of multidrug-resistant tuberculosis. Aminosalicylic acid is always used in combination with other anti-TB drugs and is never used on its own.

The dose when treating tuberculosis is 150mg/kg/day divided into two to four daily doses; the usual adult dose is therefore approximately 2 to 4g four times a day. It is sold in the US as Paser which comes in the form of 4g packets of delayed-release granules that have to be measured out with a scoop. The drug should be taken with acid food or drink (orange, apple or tomato juice).

Aminosalicylic acid used to be available in a combination formula with isoniazid called Pasinah.

Aminosalicylic acid has also used in the treatment of inflammatory bowel diseases, but has been superseded by other drugs such as sulfasalazine and mesalazine.

Pharmacology

It has a molecular weight of 153.14. With heat, aminosalicylic acid is decarboxylated to produce CO2 and m-aminophenol. Granules are tan in colour and must be refrigerated: they turn dark brown or purple when kept at room temperature for prolonged periods and should not be taken.

Aminosalicylic acid is in the FDA pregnancy category C. This means that it is not known whether it will harm an unborn baby.

Side effects

Gastrointestinal side-effects (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem. It is also a cause of drug-induced hepatitis. Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis. Thyroid goitre is also a side-effect because aminosalicylic acid inhibits the synthesis of thyroid hormones.

There are drug interactions (in particular, phenytoin levels are increased).

History

PAS was discovered by the Swedish chemist Jörgen Lehmann while he followed through on published information that the tuberculosis bacterium avidly metabolized salicylic acid. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery. The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance.

Late in the 1940s, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone.

External links


Template:WS Template:Jb1